As recently investigated in mice, WNT/β-catenin signaling blockade might be used in combination with therapeutic strategies, limiting the expression of inhibitory ligands in cancer cells such as CD47 [101] or blocking PD-1/PD-Ls interactions [118]. The gene discussed is CD47; the disease is cancer.